Table of contents
Focal segmental glomerulosclerosis
The following summarized guidelines for the evaluation and management of focal segmental glomerulosclerosis are prepared by our editorial team based on guidelines from the Kidney Disease: Improving Global Outcomes Foundation (KDIGO 2021) and the Japanese Society of Nephrology (JSN 2016).
Evaluate for secondary causes in adult patients with FSGS without nephrotic syndrome.
Consider referring selected patients with FSGS to specialized centers for genetic testing.
Corticosteroids: as per KDIGO 2021 guidelines, initiate high-dose oral corticosteroids as first-line immunosuppressive treatment in patients with primary FSGS.
Show 2 more
More topics in this section
3.Follow-up and surveillance
Management of relapse: consider managing adult patients with previous corticosteroid-sensitive primary FSGS experiencing a relapse as adult patients with relapsing minimal change disease.